Xanthus' Symadex Can Reverse Disease In Preclinical Multiple Sclerosis Animal Model
Fri, 29 Sep 2006 07:00 AM EST
... Xanthus Pharmaceuticals, Inc., a privately-held drug development company, today presented data that Symadex(TM) reverses the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis (MS). The presentation was made by Stephen J. [click link for full article] ...
Related Topics
- Disease models
- Animal Research
- Tuberous Sclerosis
- Multiple Sclerosis/ms
- Multiple Sclerosis
- Service Animals
- Multiple Myeloma
- Myeloma, Multiple
- Myeloma
- Pets and Pet Health
- Lichen Sclerosis
- Bites and Stings
- Multiple Chemical Sensitivity
- Endocrine Diseases And Disorders
- Health Promotion
- Biopsychosocial model
- Fungal Diseases
- Amyotrophic Lateral Sclerosis
- Aspartame
- Hives

Not Signed In -


